MedTrace Logo

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

NCT03170817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2021-10-26

No results posted yet for this study

Summary

Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac Perfusion Rest/Stress Digital PET/CT

Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan. These patients are given: 1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration. 2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart 3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration Total patient time will take approximately up to 120 minutes.

DRUG

N-13 ammonia

5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress

DRUG

Regadenoson

0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)

Sponsors & Collaborators

Principal Investigators

  • Guido Davidzon, MD, MS · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-29
Primary Completion
2020-03-31
Completion
2021-09-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03170817 on ClinicalTrials.gov